Fortis Group Advisors, LLC Lexicon Pharmaceuticals, Inc. Transaction History
Fortis Group Advisors, LLC
- $515 Billion
- Q1 2025
A detailed history of Fortis Group Advisors, LLC transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Fortis Group Advisors, LLC holds 37,800 shares of LXRX stock, worth $24,948. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,800Holding current value
$24,948% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LXRX
# of Institutions
140Shares Held
244MCall Options Held
52KPut Options Held
178K-
Artal Group S.A. Luxembourg, N4136MShares$89.9 Million100.0% of portfolio
-
Siren, L.L.C. New York, NY38.9MShares$25.7 Million1.27% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$6.53 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.88MShares$6.52 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.99MShares$5.93 Million0.02% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $125M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...